28-day Repeat Dose Study of GSK573719

Status:
Completed

Trial end date:
2010-07-04

Target enrollment:

Participant gender:

The study will evaluate the efficacy, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD

Phase 2

GlaxoSmithKline